RDEA Related StreetInsider.com Reports
-
Ardea Biosciences (RDEA) Gets $7.5M Milestone from Bayer for MEK Inhibitor Development
-
UBS Downgrades Ardea Biosciences (RDEA) to Neutral
-
UPDATE - Canaccord Genuity Downgraded Ardea Biosciences (RDEA) To 'Hold'; Q1 Is Non-Event In Light Of Acquisition By AZN
-
Canaccord Genuity Downgrades Ardea Biosciences (RDEA) to Hold
-
Ardea Biosciences, Inc. (RDEA) Reports Q1 Loss of $1.25/Share
-
Amarin (AMRN) Shares Rise Following M&A Chatter; Other Targets Mentioned (AMLN) (FRX)
-
William Blair Downgrades Ardea Biosciences (RDEA) to Market Perform
-
Market Wrap 4/23: Netflix Net-'fails'; Markets React to Europe; Merger Monday!; Potent Potables
-
Unusual 11 Mid-Day Movers 04/23: (RDEA) (KERX) (CEDC) Higher; (OTT) (ACHN) (NABI) Lower
-
Leerink Swann Downgrades Ardea Biosciences (RDEA) to Market Perform
-
Morning Movers 04/23: (RDEA) (KERX) (CEDC) (AMLN) Higher; (OTT) (NABI) (ACHN) Lower
-
Notable Mergers and Acquisitions of the Day 04/23: (PFE) (AZN)/(RDEA) (TRI) (NABI) (BEAM)
-
Brean Murray Carret & Co. Downgrades Ardea Biosciences (RDEA) to Hold; AstraZeneca (AZN) Steps In
-
Pre-Open Movers 4/23: (RDEA) (CEDC) (KERX) Higher; (ACHN) (K) (WMT) Lower (more...)
-
Amylin (AMLN) Shares Pop on New M&A Chatter (BMY) (AZN)
-
AstraZeneca (AZN) to Acquire Ardea (RDEA) in $1.26B Deal
-
UPDATE - UBS Initiates Coverage on Ardea Biosciences (RDEA) with a Buy; Lesinurad Knocks Out Gout
-
UBS Starts BMRN, RDEA, ARIA at Buy, ITMN, ACHN, HGSI, IRWD at Neutral
-
Canaccord Genuity Starts Ardea Biosciences (RDEA) at Buy
-
Ardea Biosciences, Inc. (RDEA) Posts Q4 Loss of $1.15; Revs Light
-
William Blair Starts Ardea Biosciences (RDEA) at Outperform
-
Ardea Biosciences (RDEA) Completes Common Stock Offering, Gross Proceeds $166.2 Million
-
Ardea Biosciences (RDEA) Lower Following Pricing of 8.5M Common Offering
-
Ardea Biosciences (RDEA) Prices 8.5M Common Offering at $17/Share
-
Collins Stewart Starts Ardea Biosciences (RDEA) at Buy; Lesinurad to Fill Hole in Gout Market
-
Ardea (RDEA) Files $150M Mixed Shelf
-
Ardea (RDEA) Initiates Potenital Gout Treatment Lesinurad Phase 3
-
Wells Fargo Starts Ardea Biosciences (RDEA) at Market Perform; Gout Market Represents A Large Opportunity
-
Correction - Noble Financial Starts Ardea Biosciences (RDEA) at Market Outperform
-
Ardea Biosciences, Inc. (RDEA) Reports Q3 Loss of $0.84, Sales Miss Expectations
-
Ardea Biosciences (RDEA) Completes Positive End-of-Phase 2 FDA Meetings for Lesinurad
-
Ardea Biosciences, Inc. (RDEA) Posts Q2 Loss of 68c, Wider than Views
-
Stifel Nicolaus Starts Ardea Biosciences (RDEA) at Buy
-
PURE Bioscience (PURE) Appoints Craig Johnson as CFO
-
Boenning & Scattergood Starts Ardea Biosciences (RDEA) at Outperform; Best-In-Class Product In An Underserved and Growing Market
-
Jefferis Remains Positive on Shares of Ardea Biosciences (RDEA) Following 28-Week Extension Data For Lesinurad-Allopurinol Combination
-
Ardea Biosciences (RDEA) Provides Additional Positive Data for Gout Treatment Lesinurad
-
Ardea Biosciences, Inc. (RDEA) Misses Q1 Views
-
Wedbush Assuming Coverage on Ardea Biosciences (RDEA) at Outperform, $37 Price Target
-
Mizuho Starts Biotech Stocks: (AMGN) (BIIB) (CELG) (ONXX) (RDEA) at Buy, (SVNT) at Neutral
-
Ardea Biosciences (RDEA) Posts Q4 Loss of $0.03; Revs Heavy
-
Piper Jaffray Cuts Ardea Biosciences (RDEA) to Neutral
-
Ardea Biosciences (RDEA) prices 2.75 million shares at $26/share
-
After-Hours Movers 01/19: NVEC, PPDI, EBAY Higher; FFIV, RVBD, BCSI, ARQL, PLXS, ISLE, CRM, RAX, STX Lower
-
Ardea (RDEA) to offer 2.5 million shares of common stock
-
Ardea Biosciences (RDEA) Receives $15M Milestone from Bayer
-
Jefferies Raises Price Target on Ardea Biosciences (RDEA), Maintains Buy Rating
-
Global Hunter Securities reiterates a 'Buy' on Ardea Biosciences (RDEA); Positive top-line Phase IIb RDEA594 Data
-
Ardea Biosciences (RDEA) Announces Positive Phase 2b Data for RDEA594 in Allopurinaol-Refractory Gout Patients
-
Brean Murray Carret & Co. Raises Price Target on Ardea Biosciences (RDEA)
Back to RDEA Stock Lookup
